Impact of CYP2D6 Genotype on Amitriptyline Efficacy for the Treatment of Diabetic Peripheral Neuropathy: A Pilot Study | Zendy

Mamoonah Chaudhry | Zendy; Marco Alessandrini | Zendy; Jacobus Rademan | Zendy; Tyren M. Dodgen | Zendy; Francois Steffens | Zendy; Danie van Zyl | Zendy; Andrea Gaedigk | Zendy; Michael S. Pepper | Zendy

Open Access

Impact of CYP2D6 Genotype on Amitriptyline Efficacy for the Treatment of Diabetic Peripheral Neuropathy: A Pilot Study

Author(s) -

Mamoonah Chaudhry,

Marco Alessandrini,

Jacobus Rademan,

Tyren M. Dodgen,

Francois Steffens,

Danie van Zyl,

Andrea Gaedigk,

Michael S. Pepper

Publication year - 2017

Publication title -

pharmacogenomics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.541

H-Index - 91

eISSN - 1744-8042

pISSN - 1462-2416

DOI - 10.2217/pgs-2016-0185

Subject(s) - cyp2d6 , medicine , amitriptyline , peripheral neuropathy , peripheral , diabetic neuropathy , pharmacology , population , drug , genotype , pharmacogenetics , diabetes mellitus , endocrinology , gene , biology , environmental health , cytochrome p450 , metabolism , biochemistry

Therapy with low-dose amitriptyline is commonly used to treat painful diabetic peripheral neuropathy. There is a knowledge gap, however, regarding the role of variable CYP2D6-mediated drug metabolism and side effects (SEs). We aimed to generate pilot data to demonstrate that SEs are more frequent in patients with variant CYP2D6 alleles.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research